Novus International, Inc.; Filing of Food Additive Petition (Animal Use); Correction, 85972 [2016-28656]

Download as PDF 85972 Federal Register / Vol. 81, No. 229 / Tuesday, November 29, 2016 / Notices TABLE 2—ESTIMATED ANNUAL REPORTING BURDEN 1—Continued Number of respondents Activity Number of completes ............................................... Number of responses per respondent 240 Total annual responses Average burden per response (in hours) Total hours 1 240 0.42 (25 minutes) ...... 101 Main Study Number to complete the screener (assumes 50% eligibility). Number of completes ............................................... 1,785 1 1,785 0.08 (5 minutes) ........ 143 1,272 1 1,272 0.42 (25 minutes) ...... 534 Total hours ........................................................ ........................ ........................ ........................ .................................... 805 1 There are no capital costs or operating and maintenance costs associated with this collection of information. asabaliauskas on DSK3SPTVN1PROD with NOTICES References The following references are on display in the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, and are available for viewing by interested persons between 9 a.m. and 4 p.m., Monday through Friday; they are also available electronically at http:// www.regulations.gov. FDA has verified the Web site addresses, as of the date this document publishes in the Federal Register, but Web sites are subject to change over time. 1. Hall R.H. and P. Hanna ‘‘The Impact of Web page Text-background Colour Combinations on Readability, Retention, Aesthetics, and Behavioural Intention.’’ Behavior & Information Technology. vol. 23 pp. 183–95, 2004. 2. Baur C and C. Prue ‘‘The CDC Clear Communication Index is a Tool to Prepare and Review Health Information.’’ Health Promotion Practice. vol.15 pp. 629–37, 2014. 3. Shrank W, J. Avorn, C. Rolon, and P.Shekelle ‘‘Effect of Content and Format of Prescription Drug Labels on Readability, Understanding, and Medication Use: A Systematic Review.’’ Annals of Pharmacotherapy. vol. 41 pp. 783–801, 2007. 4. Wogalter, M.S. and W.J. Vigilante. ‘‘Effects of Label Format on Knowledge Acquisition and Perceived Readability by Younger and Older Adults.’’ Ergonomics. vol. 46 pp. 327–344, 2003. 5. Smither, J.A.A. and C.C. Braun ‘‘Readability of Prescription Drug Labels by Older and Younger Adults.’’ Journal of Clinical Psychology in Medical Settings. vol. 1 pp. 149–59, 1994. 6. Foxman, E.R., D.D. Muehling and P.A. Moore. ‘‘Disclaimer Footnotes in Ads: Discrepancies Between Purpose and Performance.’’ Journal of Public Policy and Marketing. vol. 7 pp. 127–37, 1988. 7. Murray N.M., L.A. Manrai and A.K. Manrai. ‘‘Public Policy Relating to Consumer Comprehension of Television Commercials: A Review and Some Empirical Results.’’ Journal of Consumer Policy. vol. 16 pp. 145–170, 1993. 8. Manrai, L.A., A.K. Manrai and N. Murray. VerDate Sep<11>2014 17:48 Nov 28, 2016 Jkt 241001 ‘‘Comprehension of Info-aid Supers in Television Advertising for Social Ideas: Implications for Public Policy’’. Journal of Business Research. vol. 30 pp. 75–84, 1994. 9. Hill A. and L. Scharff. ‘‘Readability of Computer Displays as a Function of Colour, Saturation, and Background Texture.’’ In D. Harns (Ed.) Engineering Psychology and Cognitive Ergonomics (vol. 4) Ashgate, Aldershot, United Kingdom. 10. Shieh K-K. and C-C. Lin. ‘‘Effects of Screen Type, Ambient Illumination, and Color Combination on VDT Visual Performance and Subjective Preference.’’ International Journal of Industrial Ergonomics. vol. 26 pp. 527–36, 2000. 11. Tinker M.A. and D.G. Paterson. ‘‘Studies of Typographical Factors Influencing Speed of Reading. VII. Variations in Color of Print and Background.’’ Journal of Applied Psychology. vol. 15 pp. 471– 9, 1931. 12. Legge G.E., G.S. Rubin and A. Luebner ‘‘Psychophysics of reading. V. The Role of Contrast in Normal Vision.’’ Vision Research vol. 27 pp. 1165–77, 1987. 13. Kaufman D.W., J.P. Kelly, L. Rosenberg, T.E. Anderson and A.A. Mitchell. ‘‘Recent Patterns of Medication Use in the Ambulatory Adult Population of the United States: The Slone Survey.’’ Journal of the American Medical Association vol. 287 pp. 337–344, 2002. Dated: November 22, 2016. Leslie Kux, Associate Commissioner for Policy. [FR Doc. 2016–28733 Filed 11–28–16; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2016–F–3880] Novus International, Inc.; Filing of Food Additive Petition (Animal Use); Correction AGENCY: The Food and Drug Administration is correcting a notice entitled ‘‘Novus International, Inc.; Filing of Food Additive Petition (Animal Use)’’ that appeared in the Federal Register of November 8, 2016 (81 FR 78528). The document announced that Novus International, Inc., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of poly (2-vinylpyridine-co-styrene) as a nutrient protectant for methionine hydroxy analog in animal food for beef cattle, dairy cattle, and replacement dairy heifers. Additionally, the petition proposes that the food additive regulations be amended to provide for the safe use of ethyl cellulose as a binder for methionine hydroxy analog to be incorporated into animal food. The document was published with the incorrect docket number. This document corrects that error. SUMMARY: Lisa Granger, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 3330, Silver Spring, MD 20993– 0002, 301–796–9115, lisa.granger@ fda.hhs.gov. FOR FURTHER INFORMATION CONTACT: In the Federal Register of Tuesday, November 8, 2016, in FR Doc. 2016–26922, on page 78528, the following correction is made: On page 78528, in the first column, ‘‘Docket No. FDA–2014–F–0452’’ is corrected to read ‘‘Docket No. FDA– 2016–F–3880’’. SUPPLEMENTARY INFORMATION: Dated: November 22, 2016. Leslie Kux, Associate Commissioner for Policy. [FR Doc. 2016–28656 Filed 11–28–16; 8:45 am] BILLING CODE 4164–01–P Food and Drug Administration, HHS ACTION: PO 00000 Notice; correction. Frm 00053 Fmt 4703 Sfmt 9990 E:\FR\FM\29NON1.SGM 29NON1

Agencies

[Federal Register Volume 81, Number 229 (Tuesday, November 29, 2016)]
[Notices]
[Page 85972]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-28656]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2016-F-3880]


Novus International, Inc.; Filing of Food Additive Petition 
(Animal Use); Correction

AGENCY: Food and Drug Administration, HHS

ACTION: Notice; correction.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration is correcting a notice 
entitled ``Novus International, Inc.; Filing of Food Additive Petition 
(Animal Use)'' that appeared in the Federal Register of November 8, 
2016 (81 FR 78528). The document announced that Novus International, 
Inc., has filed a petition proposing that the food additive regulations 
be amended to provide for the safe use of poly (2-vinylpyridine-co-
styrene) as a nutrient protectant for methionine hydroxy analog in 
animal food for beef cattle, dairy cattle, and replacement dairy 
heifers. Additionally, the petition proposes that the food additive 
regulations be amended to provide for the safe use of ethyl cellulose 
as a binder for methionine hydroxy analog to be incorporated into 
animal food. The document was published with the incorrect docket 
number. This document corrects that error.

FOR FURTHER INFORMATION CONTACT: Lisa Granger, Food and Drug 
Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 3330, Silver 
Spring, MD 20993-0002, 301-796-9115, lisa.granger@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: In the Federal Register of Tuesday, November 
8, 2016, in FR Doc. 2016-26922, on page 78528, the following correction 
is made: On page 78528, in the first column, ``Docket No. FDA-2014-F-
0452'' is corrected to read ``Docket No. FDA-2016-F-3880''.

    Dated: November 22, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016-28656 Filed 11-28-16; 8:45 am]
 BILLING CODE 4164-01-P